AKT inhibitors are classified into three broad categories: ATP-competitive, allosteric, and covalent allosteric inhibitors, with capivasertib being the first drug to receive FDA approval in combination with the estrogen receptor degrader fulvestrant for breast cancer treatment 103. Here, AKT1 is linked to breast cancer.